Laureate Pharma (Laureate) has signed a new biopharmaceutical development and manufacturing agreement with an undisclosed client. According to the agreement, Laureate will develop the process to manufacture a unique Fc fusion protein and produce this product under cGMP conditions for use in clinical trials.
Robert Broeze, president and CEO of Laureate, said: "This project is a great fit with the experience that we have developed over the past few years working with fusion proteins. We have had great success working with these unique protein products and are delighted to have the opportunity to help advance this product into the clinic."
Dan Leone, vice president of business development at Laureate, said: "We are seeing a strong trend in the biopharmaceutical industry to develop fusion protein products with unique properties. Along with monoclonal antibodies, manufacturing fusion proteins has become one of Laureate’s core competencies."